EXC Stock Cash Flow Statements

Exelon Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Exelon Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-06-30	2024-03-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30	2022-06-30	2022-03-31	2021-06-30	2021-03-31	2020-03-31	2018-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-03-31	2012-09-30	2012-06-30	2012-03-31

cash flows from operating activities
net income	392,000,000	908,000,000	448,000,000	658,000,000	699,000,000	343,000,000	669,000,000	676,000,000	465,000,000	598,000,000	475,000,000	-264,000,000	376,000,000	636,000,000	587,000,000	634,000,000	738,000,000	1,074,000,000	558,000,000	93,000,000	1,000,000	297,000,000	290,000,000	200,000,000
adjustments to reconcile net income to net cash flows from operating activities:
depreciation, amortization, and accretion	901,000,000	905,000,000	894,000,000	880,000,000
gain on sales of assets		1,000,000													-2,000,000	-7,000,000	-1,000,000
deferred income taxes and amortization of investment tax credits	44,000,000	121,000,000	26,000,000	46,000,000	116,000,000	-19,000,000	113,000,000	113,000,000	33,000,000	110,000,000	-21,000,000	-142,000,000	-245,000,000	-14,000,000	30,000,000	82,000,000	129,000,000	326,000,000	181,000,000	-48,000,000	-610,000,000	36,000,000	126,000,000	101,000,000
net fair value changes related to derivatives	2,000,000	1,000,000		1,000,000	17,000,000			0	0	-59,000,000	-312,000,000	-178,000,000	-132,000,000	259,000,000	144,000,000	-416,000,000	-91,000,000	-229,000,000	21,000,000	730,000,000	388,000,000	-54,000,000	-250,000,000	-73,000,000
other non-cash operating activities	390,000,000	344,000,000	207,000,000	39,000,000	-15,000,000	-84,000,000	-138,000,000	-11,000,000	44,000,000	232,000,000	-161,000,000	-170,000,000	273,000,000	240,000,000	277,000,000	235,000,000	344,000,000	131,000,000	295,000,000	272,000,000	231,000,000	276,000,000	429,000,000	530,000,000
changes in assets and liabilities:
accounts receivable	-58,000,000	-402,000,000	-134,000,000	-309,000,000	-305,000,000	281,000,000	106,000,000	-254,000,000	-84,000,000	-711,000,000	356,000,000	-372,000,000	800,000,000	133,000,000	-78,000,000	523,000,000	-270,000,000	150,000,000	654,000,000	-606,000,000	-70,000,000	-174,000,000	20,000,000	394,000,000
inventories	-37,000,000	17,000,000	-37,000,000	12,000,000	-52,000,000	-58,000,000	102,000,000	-133,000,000	-113,000,000	125,000,000	-76,000,000	77,000,000	81,000,000	167,000,000	-94,000,000	-132,000,000	291,000,000	-166,000,000	-230,000,000	80,000,000	101,000,000	-33,000,000	-59,000,000	104,000,000
accounts payable and accrued expenses	359,000,000	-397,000,000	118,000,000	-238,000,000	280,000,000	-252,000,000	-482,000,000	279,000,000	253,000,000	291,000,000	89,000,000	-176,000,000	-976,000,000	-451,000,000
collateral received	-30,000,000	44,000,000						-233,000,000	547,000,000	1,142,000,000
income taxes	-62,000,000	59,000,000	-60,000,000	21,000,000	-47,000,000	74,000,000	23,000,000	-20,000,000	-54,000,000	77,000,000	77,000,000	113,000,000	-56,000,000	86,000,000	53,000,000	73,000,000	174,000,000	88,000,000	-33,000,000	17,000,000	632,000,000	206,000,000	81,000,000	178,000,000
regulatory assets and liabilities	-380,000,000	86,000,000	13,000,000	252,000,000	121,000,000	-192,000,000	-324,000,000	-313,000,000
pension and non-pension postretirement benefit contributions	-10,000,000	-292,000,000	-14,000,000	-111,000,000	-12,000,000	-41,000,000	-44,000,000	-11,000,000	-11,000,000	-574,000,000	-22,000,000	-537,000,000	-531,000,000	-331,000,000	-129,000,000	-32,000,000	-269,000,000	-17,000,000	-27,000,000	-472,000,000	-267,000,000	-41,000,000	-35,000,000	-55,000,000
other assets and liabilities	1,000,000	-195,000,000	3,000,000	-264,000,000	-164,000,000	327,000,000	-187,000,000	-63,000,000	-78,000,000	-645,000,000	-862,000,000	-1,840,000,000	-488,000,000	-495,000,000	-694,000,000	99,000,000	115,000,000	-256,000,000	-2,000,000	-278,000,000	233,000,000	-74,000,000	-235,000,000	-122,000,000
net cash flows from operating activities	1,511,000,000	1,200,000,000	1,462,000,000	992,000,000	1,531,000,000	1,277,000,000	484,000,000	901,000,000	1,458,000,000	1,782,000,000	2,399,000,000	-1,261,000,000	1,080,000,000	1,502,000,000	1,705,000,000	2,479,000,000	1,490,000,000	1,892,000,000	1,586,000,000	165,000,000	859,000,000	1,828,000,000	1,735,000,000	994,000,000
cash flows from investing activities
capital expenditures	-2,013,000,000	-1,946,000,000	-1,699,000,000	-1,767,000,000	-1,855,000,000	-1,804,000,000	-1,881,000,000	-1,672,000,000	-1,585,000,000	-1,922,000,000	-1,900,000,000	-2,140,000,000	-2,016,000,000	-1,880,000,000	-1,983,000,000	-1,676,000,000	-1,784,000,000	-1,613,000,000	-1,284,000,000	-1,217,000,000	-1,447,000,000	-1,329,000,000	-1,320,000,000	-1,496,000,000
free cash flows	-502,000,000	-746,000,000	-237,000,000	-775,000,000	-324,000,000	-527,000,000	-1,397,000,000	-771,000,000	-127,000,000	-140,000,000	499,000,000	-3,401,000,000	-936,000,000	-378,000,000	-278,000,000	803,000,000	-294,000,000	279,000,000	302,000,000	-1,052,000,000	-588,000,000	499,000,000	415,000,000	-502,000,000
proceeds from sales of assets
other investing activities	-9,000,000	4,000,000	1,000,000	-2,000,000	15,000,000	0	10,000,000	32,000,000	58,000,000	-54,000,000	5,000,000	12,000,000	-8,000,000	3,000,000	-30,000,000	-75,000,000	-2,000,000	-29,000,000	-3,000,000	-54,000,000	40,000,000	53,000,000	47,000,000	-59,000,000
net cash flows used in investing activities	-2,020,000,000	-1,942,000,000	-1,700,000,000	-1,767,000,000	-1,840,000,000	-1,804,000,000	-1,871,000,000	-1,640,000,000					-2,075,000,000	-1,857,000,000	-2,143,000,000	-1,795,000,000	-1,751,000,000	-1,189,000,000	-1,176,000,000	-1,011,000,000	-1,471,000,000	-1,341,000,000	-1,344,000,000	-640,000,000
cash flows from financing activities
changes in short-term borrowings	25,000,000	-775,000,000	-353,000,000	-317,000,000	484,000,000	-470,000,000	-1,130,000,000	262,000,000	103,000,000	-700,000,000	-1,263,000,000	597,000,000	109,000,000	726,000,000	136,000,000	235,000,000	-141,000,000	-57,000,000	-345,000,000	638,000,000
proceeds from short-term borrowings with maturities greater than 90 days			0	150,000,000	0			0	0	1,150,000,000	0	500,000,000	500,000,000	1,000,000
repayments on short-term borrowings with maturities greater than 90 days			-399,000,000	-150,000,000	0	0	-150,000,000	-575,000,000	0	-350,000,000				-1,000,000
issuance of long-term debt	1,375,000,000	2,425,000,000	1,600,000,000	2,625,000,000	100,000,000	1,275,000,000	3,925,000,000	650,000,000	850,000,000	4,301,000,000	750,000,000	1,705,000,000	2,652,000,000	1,130,000,000	2,000,000	4,701,000,000	1,206,000,000	1,112,000,000	1,150,000,000	950,000,000	149,000,000	708,000,000
retirement of long-term debt			-2,000,000	-901,000,000	0	-352,000,000	-857,000,000	-360,000,000	-1,701,000,000	-6,000,000	-551,000,000	-79,000,000	-1,032,000,000	-1,241,000,000	-37,000,000	-1,128,000,000	-580,000,000	-23,000,000	-41,000,000	-1,150,000,000	-1,000,000	-82,000,000	-198,000,000	-451,000,000
issuance of common stock	0	173,000,000
dividends paid on common stock	-405,000,000	-403,000,000	-380,000,000	-381,000,000	-357,000,000	-359,000,000	-358,000,000	-336,000,000	-331,000,000	-332,000,000	-373,000,000	-374,000,000	-373,000,000	-333,000,000	-282,000,000	-268,000,000	-269,000,000	-266,000,000	-267,000,000	-266,000,000	-450,000,000	-453,000,000	-423,000,000	-350,000,000
proceeds from employee stock plans			11,000,000	11,000,000	11,000,000	9,000,000	10,000,000	9,000,000	8,000,000	9,000,000	16,000,000	31,000,000	30,000,000	12,000,000	8,000,000	8,000,000	8,000,000	7,000,000	11,000,000	7,000,000	12,000,000	19,000,000	30,000,000	12,000,000
other financing activities	-21,000,000	-35,000,000	-12,000,000	-55,000,000	-17,000,000	-24,000,000	-60,000,000	-37,000,000	-22,000,000	-62,000,000	-18,000,000	-46,000,000	-21,000,000	-30,000,000	-6,000,000	-43,000,000	-16,000,000	-75,000,000	-55,000,000	-28,000,000	-45,000,000	-10,000,000	-9,000,000	-1,000,000
net cash flows from financing activities	178,000,000	1,385,000,000	465,000,000	982,000,000	221,000,000	479,000,000	1,380,000,000	176,000,000	-1,093,000,000	1,416,000,000	-1,439,000,000	2,334,000,000	1,865,000,000	264,000,000	1,689,000,000	3,505,000,000	208,000,000	698,000,000	38,000,000	151,000,000		-136,000,000	237,000,000	-649,000,000
increase in cash, restricted cash, and cash equivalents	-331,000,000	643,000,000	227,000,000	207,000,000		-48,000,000	-7,000,000	-563,000,000	-1,162,000,000	1,379,000,000	-325,000,000	1,168,000,000
cash, restricted cash, and cash equivalents at beginning of period	0	939,000,000	0	1,101,000,000	0	0	1,090,000,000	0	0	1,619,000,000	0	1,166,000,000
cash, restricted cash, and cash equivalents at end of period	-331,000,000	1,582,000,000	227,000,000	1,308,000,000	-88,000,000	-48,000,000	1,083,000,000	-563,000,000	-1,162,000,000	2,998,000,000	-325,000,000	2,334,000,000
supplemental cash flow information
decrease in capital expenditures not paid	116,000,000	-216,000,000	43,000,000	-117,000,000	-5,000,000	37,000,000	-201,000,000	129,000,000	46,000,000	-322,000,000	11,000,000	-324,000,000	-180,000,000
collateral received (paid)			6,000,000	7,000,000
gain on sales of assets and businesses				-2,000,000				0	2,000,000	-10,000,000	-12,000,000	-71,000,000		-56,000,000
proceeds from sales of assets and businesses				2,000,000				0	0	16,000,000	44,000,000	680,000,000		79,000,000
depreciation, amortization, and accretion, including nuclear fuel and energy contract amortization					889,000,000	867,000,000	860,000,000	825,000,000	830,000,000	1,024,000,000	2,076,000,000	2,104,000,000
asset impairments											499,000,000	1,000,000	8,000,000
net realized and unrealized losses on ndt funds
net unrealized losses on equity investments										16,000,000
option premiums paid														-27,000,000							-3,000,000
collateral (paid) received					4,000,000	27,000,000	-214,000,000
proceeds from ndt fund sales								0	0	488,000,000	1,530,000,000	2,908,000,000	1,183,000,000
investment in ndt funds								0	0	-516,000,000	-1,599,000,000	-2,939,000,000	-1,234,000,000
collection of dpp								0	0	169,000,000	635,000,000	1,574,000,000
transfer of cash, restricted cash, and cash equivalents to constellation								0	0	-2,594,000,000
decrease in cash, restricted cash, and cash equivalents
increase in dpp								0	0	348,000,000	619,000,000	1,339,000,000
increase in pp&e related to aro update								666,000,000	0	-335,000,000
decrease in pp&e related to aro update
net realized and unrealized losses (gains) on ndt funds								0	0	205,000,000			651,000,000
acquisition of ceng noncontrolling interest
net unrealized losses (gains) on equity investments
option premiums (paid) received									0	-39,000,000			-38,000,000									-14,000,000	-8,000,000	-100,000,000
net cash flows from investing activities										-1,819,000,000		95,000,000
net realized and unrealized (gains) losses on ndt funds											-258,000,000	-118,000,000
net unrealized gains on equity investments
option premiums received (paid)											-14,000,000	16,000,000						0	6,000,000	15,000,000
unrealized loss on equity investments												23,000,000
collateral received (posted)												273,000,000
depreciation, amortization and accretion, including nuclear fuel and energy contract amortization													1,378,000,000	1,501,000,000
collateral posted													-21,000,000	-214,000,000
increase in cash, cash equivalents and restricted cash													870,000,000
cash, cash equivalents and restricted cash at beginning of period													1,122,000,000	1,190,000,000
cash, cash equivalents and restricted cash at end of period													1,992,000,000	1,099,000,000
increase in ppe related to aro update
impairment of long-lived assets and losses on regulatory assets
bargain purchase gain
net realized and unrealized gains on nuclear decommissioning trust fund investments														68,000,000		45,000,000	-47,000,000	27,000,000	-142,000,000	-26,000,000	-66,000,000		33,000,000	-103,000,000
proceeds from nuclear decommissioning trust fund sales														1,189,000,000	1,237,000,000	1,633,000,000	1,681,000,000	1,245,000,000	2,394,000,000	1,825,000,000	677,000,000	891,000,000	1,691,000,000	3,680,000,000
investment in nuclear decommissioning trust funds														-1,248,000,000	-1,300,000,000	-1,690,000,000	-1,747,000,000	-1,312,000,000	-2,360,000,000	-1,878,000,000	-729,000,000	-939,000,000	-1,757,000,000	-3,726,000,000
acquisition of businesses															0	-13,000,000	-15,000,000
decrease in cash, cash equivalents and restricted cash														-91,000,000
depreciation, amortization, depletion and accretion, including nuclear fuel and energy contract amortization															973,000,000	1,009,000,000	948,000,000	931,000,000	1,017,000,000	908,000,000	1,017,000,000
impairment of long-lived assets															1,000,000
gain on consolidation and acquisition of businesses
net realized and unrealized (gains) losses on nuclear decommissioning trust fund investments
accounts payable, accrued expenses and other current liabilities															521,000,000	-61,000,000	-607,000,000	36,000,000	-515,000,000	157,000,000	-542,000,000	226,000,000	113,000,000	-1,176,000,000
option premiums received															5,000,000	17,000,000	5,000,000
counterparty collateral received (posted)															-112,000,000	386,000,000	31,000,000				-186,000,000	-43,000,000	111,000,000	340,000,000
proceeds from sale of long-lived assets															0	3,000,000	142,000,000	628,000,000	14,000,000	18,000,000
proceeds from termination of direct financing lease investment																		0	0	335,000,000
proceeds from sales of investments																						14,000,000	2,000,000	10,000,000
cash and restricted cash acquired from consolidations and acquisitions
change in restricted cash															-67,000,000	23,000,000	-26,000,000	-111,000,000	0	-40,000,000	-12,000,000	-23,000,000	-7,000,000	-8,000,000
distributions to noncontrolling interest of consolidated vie
increase in cash and cash equivalents															1,251,000,000							351,000,000
cash and cash equivalents at beginning of period															0	0	1,878,000,000	0	0	1,609,000,000	1,486,000,000	0	0	1,016,000,000
cash and cash equivalents at end of period															1,251,000,000	4,189,000,000	1,825,000,000	1,401,000,000	448,000,000	914,000,000	772,000,000	351,000,000	628,000,000	721,000,000
decrease in cash and cash equivalents																	-53,000,000		448,000,000	-695,000,000	-714,000,000			-295,000,000
gain on consolidation of ceng																		0
gain on sale of assets
counterparty collateral posted																		-9,000,000	71,000,000	-677,000,000
proceeds from sale of investments
purchases of investments																						-8,000,000	0	-5,000,000
cash consolidated from ceng																		0
payment of accounts receivable agreement
redemption of preferred securities
acquisition of business
distributions to non-controlling interest of consolidated vie
impairment of assets held for sale
counterparty collateral (posted) received
cash and restricted cash acquired from constellation
changes in short-term debt																					233,000,000	-318,000,000	38,000,000	141,000,000
dividends paid to former constellation shareholders																						0
net cash flows used in financing activities																					-102,000,000
depreciation, amortization, accretion and depletion including nuclear fuel and energy contract amortization																						1,014,000,000	1,119,000,000	776,000,000
acquisitions
cash acquired from constellation																						0	0	964,000,000
depreciation, amortization and accretion, including nuclear fuel amortization
retirement of long-term debt of variable interest entity

We provide you with 20 years of cash flow statements for Exelon stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Exelon stock. Explore the full financial landscape of Exelon stock with our expertly curated income statements.

The information provided in this report about Exelon stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.